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ABBREVIATIONS 
ADAM Advanced Dissolution, Absorption and Metabolism 
BMI  Body mass index 
CNS   Central nervous system 
CRF   Controlled-release formulation  
EC50  Half maximal effective concentration 
PBPK  Physiological-based pharmacokinetic modelling 
pKa  acid dissociations constant 
PKPD  Pharmacokinetic-pharmacodynamic modelling 
RYGB Roux-en-Y gastric bypass 
SBS  Short bowel syndrome 




Gastrointestinal surgery, associated with resection or bypass, challenges the use of 
orally administered drugs, as drug absorption may be altered.  Approximately, 14 % 
of gastrointestinal postsurgical patients are chronic opioid users. The consequence that 
patients may in one end of the spectrum experience inadequate pain relief and in the 
other end severe side-effects such as respiratory depression and excessive sedation. 
Oxycodone is one of the most commonly used opioids for treatment of moderate to 
severe pain. The aim of this PhD thesis was therefore to investigate the impact of 
gastrointestinal surgery on the pharmacokinetics and pharmacodynamics of different 
oral oxycodone formulations, as a model for drug absorption in general.  
 
First, to obtain more knowledge of gastrointestinal physiology relating to drug 
absorption after surgery, 19 patients with Roux-en-Y gastric bypass (RYGB) 
underwent a standardized assessment using the wireless motility capsule. This capsule 
can determine the pH, transit time and motility activity of the different gastrointestinal 
segments. Compared to healthy age- and gender-matched participants, the oro-cecal 
segment (stomach and small intestine) was characterized by accelerated transit, 
elevated pH and motility activity, whereas transit time through the colon was longer 
in patients with RYGB.  
 
Secondly, a randomized, cross-over study was conducted to assess and evaluate the 
exposure-response relationship of oral solution, lipid-based and water-swellable 
controlled-release oxycodone formulations administered in 15 healthy participants 
and 21 patients with RYGB. Pupil diameter was used as a biomarker for the 
pharmacodynamic profile of oxycodone. A pharmacokinetic-pharmacodynamic 
model was developed. The model could not demonstrate any pharmacokinetic 
differences between the two controlled-release formulations in neither of the 
populations. In comparison to healthy participants, bioavailability of oxycodone was 
elevated in patients with RYGB.  
 
Thirdly, two full physiological-based pharmacokinetic models (oral solution and 
controlled-release oxycodone), with absorption predicted using the Advanced 
Dissolution, Absorption and Metabolism model, were successfully developed and 
verified against published clinical data. Additionally, simulations in healthy 
populations of varying age and ethnicity as well as patients with renal and hepatic 
impairment indicated a need for dose adjustments, which was in reasonable agreement 
with published data.  
 
Lastly, the absorption profile of oxycodone administered as an oral solution was 
explored by performing a pharmacokinetic study in six patients with short bowel 
syndrome. Expectedly, the absorption fraction was significantly reduced in patients 
with short bowel syndrome compared to reference values obtained in healthy 
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participants. A positive correlation tended to be present between functional intestinal 
length and fraction absorbed. Furthermore, maintenance of the colon seemed 
favorable in regard to higher oxycodone bioavailability (absorption fraction). 
 
In conclusion, gastrointestinal surgery, associated with resection or bypass, impacts 
the absorption of orally administered oxycodone. In patients with RYGB, the 
physiochemical properties of a drug may be superior to the formulation design in 
regard to altered pharmacokinetics. Hence, any of the tested formulations can be 
prescribed to patients with RYGB, but the increased bioavailability of oxycodone may 
necessitate dose adjustments to prevent side-effects such as respiratory depression and 
sedation. This may be further addressed using a combination of pharmacokinetic-
pharmacodynamic and physiological-based pharmacokinetic modelling. In patients 
with short bowel syndrome, lack of functional intestine tended to influence the 
absorption of oxycodone. Nevertheless, oral solution oxycodone may be used in 
patients with short bowel syndrome, although drug dosing must be individualized and 
most patients will presumably require higher doses to obtain therapeutic efficacy. 
Future studies may apply our results to further develop physiological-based 
pharmacokinetic models in patients with different gastrointestinal diseases and assist 









Mave-tarm-kanalens blodforsyning, fysiologi og funktion har stor betydning for 
hvorledes et lægemiddelstof frisættes fra en lægemiddelformulering og optages til 
blodbanen. Af denne årsag kan lægemiddeldosering til patienter med fysiologiske 
forandringer i mave-tarm-kanalen, som f.eks. korttarmssyndrom eller gastrisk bypass, 
være en udfordring. Den forandrede fysiologi kan medføre at patienterne bliver under- 
eller overdoseret selvom de modtager standarddosis. En del patienter med 
forandringer i mave-tarm-kanalen har kroniske smerter og har behov for 
smertestillende medicin. Oxycodon er et af de mest anvendte opioider til behandling 
af moderate til svære smertetilstande. For at kunne optimere kvaliteten og sikkerheden 
af fremtidige behandlinger er det således relevant at undersøge, hvorledes kirurgi i 
mave-tarm-kanalen, i form af resektion eller bypass, påvirker den farmakokinetiske 
og –dynamiske profil af oxycodon administreret i forskellige lægemiddel-
formuleringer.  
Transittid, pH og motilitet blev karakteriseret i de forskellige gastrointestinale 
segmenter hos 19 patienter med Roux-en-Y gastrisk bypass (RYGB) ved brug af en 
trådløs motilitetskapsel (wireless motility capsule). Sammenlignet med 
referenceværdier fra raske personer var det oro-cecale segment (mavesæk og 
tyndtarm) hos patienter med RYGB karakteriseret ved kortere transittid samt øget pH 
og motilitet, mens transittiden i tyktarmen var længere. 
Et randomiseret overkrydsningsstudie, undersøgte dernæst den farmakokinetiske og -
dynamiske profil af oxycodon administreret som oral opløsning, lipid-baseret- og 
kvældbar-depottablet i 15 raske forsøgsdeltagere og 21 patienter med RYGB. 
Pupildiameteren blev anvendt som biomarkør for den farmakodynamiske profil. 
Baseret på disse data blev en farmakokinetisk-farmakodynamisk model udviklet. 
Modellen viste, at der ikke var farmakokinetiske forskelle mellem de to 
depotformuleringer, hverken hos raske forsøgsdeltagere eller patienter med RYGB. 
Dog havde oxycodon generelt en højere biotilgængelighed i patienter med RYGB 
sammenlignet med raske deltagere.  
To fysiologisk-baseret farmakokinetiske modeller (oral opløsning og depottablet 
oxycodon) blev herefter udviklet og verificeret ift. klinisk observerede data. 
Lægemiddelabsorptionen blev beskrevet vha. den såkaldte Advanced Dissolution, 
Absorption and Metabolism model, som tillader simulering af absorptionen af 
oxycodon efter administration af forskellige formuleringer samt at undersøge effekten 
af forskellige fysiologiske forandringer i mave-tarm-kanalen. De to verificerede 
modeller blev brugt til at simulere farmakokinetiske parametre i raske populationer 
med varierende alder og etnicitet såvel som patienter med nedsat nyre- og 
leverfunktion. Simuleringerne indikerede et behov for dosisjusteringer, hvilket var i 
rimelig overensstemmelse med tidligere publicerede data.  
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Sidst, men ikke mindst, blev den farmakokinetiske profil for oxycodon, givet som oral 
opløsning, bestemt i seks patienter med korttarmsyndrom. I sammenligning med 
referenceværdier fra raske personer, var absorptionsfraktionen af oxycodon hos 
patienter med korttarmsyndrom som forventet lavere. Der sås en tendens til en positiv 
sammenhæng mellem funktionel tarmlængde og biotilgængelighed 
(absorptionsfraktion). Bevaring af tyktarmen syntes desuden at være en fordel ift. en 
højere biotilgængelighed (absorptionsfraktion) af oxycodon. 
Kirurgi i mave-tarm-kanalen, i form af resektion eller bypass, påvirker absorptionen 
af oralt administreret oxycodon. Hos patienter med RYGB lader det til, at de fysisk-
kemiske egenskaber af et lægemiddel har en større betydning for en eventuel ændret 
lægemiddelabsorption sammenlignet med selve frisætningsmekanismen af forskellige 
depottabletter. Generisk substitution af depottabletterne, der indgik i undersøgelsen, 
er sikker at anvende for patienter med RYGB. Dosisjusteringer bør overvejes pga. den 
øgede biotilgængelighed hos patienter med RYGB. Mere specifikke anbefalinger kan 
forudsiges ved en kombination af farmakokinetisk-farmakodynamisk og fysiologisk-
baseret farmakokinetiske modellering. Hos patienter med korttarmsyndrom, var der 
en umiddelbar sammenhæng mellem absorptionen af oxycodon og funktionel 
tarmlængde. Sidst, men ikke mindst, kan oxycodon, administreret som en oral 
opløsning, anvendes til patienter med korttarmsyndrom. Lægemiddeldosering skal 
dog individualiseres, og de fleste patienter vil sandsynligvis, som følge af den lavere 
biotilgængelighed, kræve højere doser for at opnå terapeutisk virkning.  
Resultaterne fra undersøgelserne kan i fremtiden bruges til videreudvikling af 
fysiologisk-baseret farmakokinetiske modeller for patienter med forskellige 
gastrointestinale sygdomme. Dette kan på sigt medvirke til en individualisering og 
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CHAPTER 1. INTRODUCTION  
Oral drug formulations are most widely used for the pharmacological treatment of 
diseases. However, the release rate and hence its absorption is highly dependent on 
the gastrointestinal physiology, where factors such as composition of gastrointestinal 
fluids, motility surface area, transporter expression or simply resection play a major 
role. Thus, therapeutic failure may appear in patients who have pathophysiological 
changes of the gastrointestinal tract. 
1.1. ROUX-EN-Y GASTRIC BYPASS 
The Roux-en-Y gastric bypass (RYGB) is one of the most commonly performed 
bariatric surgeries in the world due to its effectiveness against morbid obesity and 
obesity related diseases such as diabetes mellitus type 2, obstructive sleep apnea, 
hypertension etc. The large, sustainable weight loss is achieved by laparoscopically 
dividing the stomach into a small upper pouch (approx. 30 mL in size) and a gastric 
remnant. Approx. 75 cm distal to the Treitz, the jejunum is anastomosed end-to-side 
to the pouch. Finally, the biliopancreatic limb is anastomosed side-to-side with the 
alimentary limb approximately 150 cm distal to the pouch (Figure 1). This 
gastrointestinal reconstruction creates a Y-configuration, hence the name “Roux-en-
Y”. More importantly, it restricts ingestion of large food quantities and affects nutrient 
uptake, as large portions of the stomach as well as the entire duodenum and initial 
parts of the jejunum are bypassed. Furthermore, it causes hormonal changes that 
induce a feeling of satiety (1). Factors which all favor weight-loss.  
 
Figure 1. Anatomical differences before (left) and after Roux-en-Y gastric bypass surgery 
(right).  
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In the period of 2009-2018 a total of 165.138 RYGB operations were conducted in 51 
different countries (2). This number is likely to be increasing, as developing countries 
become more industrialized and the global obesity epidemic continues(1). Patients 
with RYGB may constitute a growing health care concern, as postsurgical 
complications are rather common. Short-term complications may include anastomotic 
leak, small bowel obstruction, gastrointestinal hemorrhage, dumping syndrome. 
Long-term complications may include anastomotic stricture, abdominal pain, internal 
hernias, gall stone formation and nutritional deficiency (3). Hence, other surgery 
procedures with less complications such as “gastric sleeve” are increasingly in use. 
Results from several studies have also demonstrated altered drug pharmacokinetics 
following RYGB surgery (4,5), which is concerning as many patients are or will be 
prescribed oral drugs in relation to postsurgical complications, metabolic co-
morbidities, psychological conditions or simply age-related diseases. Figure 2 
illustrates physiological alterations that may affect the pharmacokinetics of orally 
administered drugs.   
 
Figure 2. Physiological alterations following RYGB surgery that may affect the 
pharmacokinetics and subsequent pharmacodynamics of orally administered drugs.  
The European Guidelines on Metabolic and Bariatric Surgery recommend substitution 
of modified-release formulations to immediate-release formulations to minimize risks 
of reduced drug absorption (6). However, recommendations are not evidence-based. 
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Additionally, results from a study showed that 75 % of bariatric patients admitted to 
the hospital were administered modified-release formulations and that only 50 % of 
these were deprescribed at discharge (7).  
Until now, only few studies have addressed the impact of RYGB surgery on drug 
absorption from modified-release formulations (8–10). In general, the aim of these 
studies was to determine the effects of surgery-related weight loss on drug 
pharmacokinetics rather than the surgery itself, as pharmacokinetics was assessed 
before and shortly after RYGB surgery. Furthermore, the significance of altered 
pharmacological effects was not assessed. Hence, results were inconclusive with 
respect to long-term recommendations. Another study addressed the 
pharmacokinetics of controlled-release oxycodone in patients after total gastrectomy 
(11). As expected, the absorption of oxycodone was not altered, since the release of 
oxycodone from the used formulation was not affected by pH. In none of the 
abovementioned studies the possible impact of altered release from mechanistically 
different controlled-release formulations (CRF) was investigated. However, bile salt- 
and fat malabsorption as well as altered gastrointestinal pH and fluid composition 
could potentially affect drug release and subsequent absorption from lipid-based and 
water-swellable matrix systems (see section 1.3.2.1). Thus, studies acquiring such 
information are highly warranted and of outmost clinical importance as results will 
promote the development of evidence-based treatment algorithms with guidance on 
appropriate formulation choice. This will be of benefit for patients, society and the 
pharmaceutical industry. 
1.2. SHORT BOWEL SYNDROME 
Short bowel syndrome (SBS) is a rare, but lifechanging and burdensome 
malabsorptive condition associated with several complications, frequent 
hospitalization, high mortality rates, psychological challenges and poor quality of life 
(12–17). It is estimated that three patients are newly diagnosed per million per year 
(18). The prevalence does, however, vary greatly between countries ranging from 0.4 
to 30 and 40 cases per million in Poland, United States and Denmark, respectively 
(14). Furthermore, SBS occurs more frequently among women than men and approx. 
15 % of adults undergoing major intestinal resections are consequently diagnosed with 
SBS (19).  
In adults, SBS is defined by a length of functional short bowel less than 200 cm 
combined with a need of nutritional and fluid supplements  (20). The condition is most 
often a result of congenital intestinal disease or extensive resection necessitated in 
relation to e.g. Crohn’s disease, neoplasms, mesenteric ischemia, radiation enteritis, 
trauma or different benign conditions (14). The list of possible symptoms and 
complications is long, some examples include diarrhea, abdominal pain, nutrient and 
fluid deficiencies, which among other factors may lead to steatorrhea, intestinal 
IMPACT OF GASTROINTESTINAL SURGERY ON ABSORPTION OF OXYCODONE 
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failure-associated liver disease, hyponatremia, renal failure, nephrolithiasis, 
hypomagnesemia, D-lactic acidosis and osteopenia (21).  
Patients with SBS are classified by their anatomy as having a stoma or preserved 
intestinal continuum with either end-jejunostomy, jejunoileal anastomosis or 
jejunocolonic anastomosis. The pathophysiology of SBS changes with time and can 
be categorized into 3 phases: i) acute phase, ii) adaptive phase and iii) maintenance 
phase (20).  
The acute phase occurs the first 3-4 weeks post-resection. It is marked by the 
significant intestinal loss giving rise to metabolic derangements, hypergastrinemia 
and gastric hypersecretion as hormone signaling pathways are dysregulated 
(20,22,23). During this phase close patient monitoring is vital to prevent serious 
complications such as dehydration and acute kidney failure. 
The adaptive phase occurs 1-2 years post-surgery and is characterized by intestinal 
adaption with elongation and enlargement of the intestinal villi as well as peristalsis 
deceleration, thus maximizing capacity and time for fluid and nutrient absorption 
(23,24).  
The final phase is the maintenance phase, which deals with management and 
prevention of SBS complications. Maintenance of a good nutritional status is superior, 
although often accompanied by pharmacotherapy (20). Oral drug therapy is preferred 
due to its convenience for patients, however, opposes major challenges for the 
prescribing physician, which must titrate doses by trial and error with high risks of 
serious advent events or no clinical effects (25–27). 
To date, limited studies investigating the absorption of orally administered drugs have 
been conducted in patients with SBS and most are case reports or studies with few 
participants. Nevertheless, in the review by Santamaría et al. all studies shows altered 
drug bioavailability and large inter-individual variation (28). Results and therapy 
recommendations do, however, deviate greatly between different drugs and 
formulations. This emphasizes the main drawback of oral formulations, namely 
absorption variability, which is a result of the interplay between three key elements: 
i) formulation design, ii) individual characteristics and iii) physiochemical drug 
properties (Figure 3). To improve drug therapy for this complex patient population 
additional investigations are needed and should ideally aim at investigating the 




Figure 3. Factors that interact and affect the process and outcome of oral drug absorption. 
1.3. FORMULATION DESIGN  
Pharmaceutical formulations can have great impact on drug absorption as they can 
control the time, rate and concentration of drug release. Numerous formulation 
designs have evolved over the years to ensure plasma concentrations fall within the 
therapeutic index of a drug and to reduce dosing frequency of drugs with short 
elimination half-lives.  
The following section will focus on the enteral forms: oral liquid dosage forms and 
oral solid dosage forms, which were applied in the studies of this PhD project.  
1.3.1. ORAL LIQUID DOSAGE FORMS 
The oral liquid dosage form is a homogenous preparation typically consisting of a 
solution, an emulsion or a suspension. An oral solution was used in this PhD project. 
Oral solutions have no dissolution parameter, thus enabling immediate drug 
absorption resulting with a rapid onset and offset of action. In comparison to 
controlled-release formulations, the main disadvantages are a shorter duration of 
action and higher peak concentrations, which may result with increased dosing 
frequency, additional and/or worse side-effects.  
The terms “oral solution”, “oral liquid” and “immediate-release formulation” are used 
interchangeably throughout this thesis and included papers. 
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1.3.2. ORAL SOLID DOSAGE FORMS 
The oral solid dosage form comes in varies forms such as tablets, capsules, powders 
and granules. Tablets and capsules can be designed in several ways to affect drug 
release. Some are designed to have an immediate drug release and are termed 
“immediate-release” tablets or capsules. Others have a modified drug release and may 
be categorized as either a prolonged-, extended-, targeted-, biphasic-, delayed-, 
sustained- or controlled-release formulation, depending on the drug release design.  
1.3.2.1 Controlled-release formulations 
Over the past decades, the controlled-release formulation has emerged greatly due to 
its prolonged and stabile drug-release profile and consequently giving a nearly 
constant absorption rate. Thus, reducing dosing frequency and fluctuations in the 
plasma concentration, which limits side-effects and increases patient compliance (29). 
Various designs of controlled-release tablets exist. Each have a specific drug-release 
mechanism. The following section will describe the differences between controlled-
release forms with a lipid and hydrophilic matrix system.  
Lipid matrix system 
A lipid matrix system consists of waxes or similar materials. Drug release is dependent 
on tablet erosion by bile acids and lipases found in the digestive fluids of the stomach 




Figure 4. Mechanism of drug release for a controlled-release tablet with a lipid matrix system. 
CRF: controlled-release formulation.  
Hydrophilic matrix system 
A hydrophilic matrix system consists of polymers with a gelling property. Drug 
release is triggered by the contact of fluids, whereby an outer gel layer is formed and 
the drug can slowly escape through small pores (31) (Figure 5). This matrix system is 
also called a water-swellable matrix system and will from hereon be referred to as 
such.  
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Figure 5. Mechanism of drug release for a controlled-release tablet with a water-swellable 
matrix system. CRF: controlled-release formulation.  
Optimal drug release from lipid-based and water-swellable matrix systems is clearly 
dependent on specific factors of the gastrointestinal tract. Thus, therapeutic failure 
may appear in patients who have pathophysiological changes of the gastrointestinal 
tract. 
1.4. OXYCODONE 
Oxycodone was used as a model substance in this PhD project for several reasons. 
First of all, a results from recent epidemiological study revealed that 14.4 % of 
gastrointestinal postsurgical patients are chronic opioid users and that oxycodone was 
the most commonly used opioid (32). Secondly, oxycodone has few active 
metabolites, which was an advantage in regard to the modelling work. Lastly, 
oxycodone exists in a wide variety of formulations.  
Oxycodone is an opioid agonist, which was first synthesized from the opiate alkaloid, 
thebaine, in 1916 and the following year prescribed for severe to moderate pain on the 
German market. However, it was not until the launch of a controlled-release 
formulation in 1995, that the global oxycodone consumption increased dramatically, 
and in 2000 it exceeded the consumption of morphine (33).  
1.4.1. PHARMACOKINETICS 
After oral administration the bioavailability of oxycodone varies between 60-87% 
(34–36). Once in the blood 38-45% is protein-bound, primarily to albumin and to less 
an extent α1-glycoprotein (5-10%) (37). Maximum plasma concentrations are reached 
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after approx. 1 hour and 3 hours for oral solution and controlled-release oxycodone, 
respectively (36,38).  
The volume of distribution after intravenous administration has been estimated to 2.6 
L/kg, confining the drug to the plasma and reflecting the high degree of plasma protein 
binding (39). Furthermore, oxycodone penetrates the blood-brain barrier without the 
need of an active transporter, according to rat and sheep data (40,41). The active 
metabolite oxymorphone does, however, seem to depend on an unknown active 
transporter (42). 
Oxycodone is primarily metabolized by the cytochrome P450 enzymes CYP3A4/5 to 
noroxycodone (accounting for 45%) and CYP2D6 to oxymorphone (accounting for 
19%)(43,44). Noroxycodone and oxymorphone are further metabolized to 
noroxymorphone by CYP2D6 and CYP3A4/5, respectively (Figure 6). The 
biotransformation of oxymorphone to noroxymorphone is, however, considered 
negligible based on in vitro data (44). Other metabolites are formed by reduction and 
glucuronidation pathways. In vitro data has shown that oxycodone undergoes 
glucuronidation primarily by the UDP-glucuronosyltransferases (UGTs) UGT2B7 
and UGT2B4. Elimination of oxycodone through this pathway is, however, minor 
(45). Oxymorphone is also glucuronidated by UGT2B7, while it remains unknown 
how noroxycodone undergoes glucuronidation (46,47). 
 
Figure 6. Biotransformation of oxycodone to its three main metabolites.  
Elimination of oxycodone and its metabolites occurs predominately through the 
kidneys (72 %), with 8% unchanged oxycodone and the remaining as metabolites 
(47% as oxidative metabolites)(43). Plasma clearance has been estimated to 0.8 
L/min. The elimination half-life is 4-5 hours for controlled-release oxycodone tablets 
and 3 hours for oral solution oxycodone (43,48).  
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1.4.2. PHARMACODYNAMICS 
Despite oxycodone being known for more than a century, the mechanism of action 
has still not been fully identified. What we do know is that oxycodone and its’ 
metabolites bind selectively to the my (µ), delta (δ) and kappa (κ) opioid receptors, 
with highest affinity for the µ-opioid receptor, and thus triggers a G-protein coupled 
receptor signaling pathway, whereby the release of nociceptive neurotransmitters (e.g. 
substance P, glutamate, dopamine, acetylcholine, noradrenaline and gamma-
aminobutyric acid) is inhibited, subsequently limiting the transmission of pain. 
Furthermore, oxycodone blocks N-voltage gated potassium channels, causing 
hyperpolarization and a dampened neuronal excitability (49,50).   
Oxycodone’s binding affinity to the µ-opioid receptor is 5-fold less than morphine 
(43). Noroxycodone binds to the µ-opioid receptor with a 3-fold lower affinity 
compared to oxycodone (43). In contrast, is the binding affinity to the µ-opioid 
receptor 10-45-fold higher for oxymorphone and two-to-four-fold higher for 
noroxymorphone compared to oxycodone (43,51).  
The analgesic potency of noroxycodone is 5- to 10- fold less than oxycodone. On the 
other hand, oxymorphone is 8- to 44-fold more potent and noroxymorphone is 2-3 
times as potent as oxycodone (43).  
The brain-to-plasma partitioning is much higher for oxycodone compared to its’ 
metabolites, presumable due to differences in lipophilicity, which limits penetration 
across the blood brain barrier (43). Noroxycodone is recognized as an inactive 
metabolite and the analgesic contribution of noroxymorphone is also considered 
negligible due to its limited blood brain barrier penetration (43,52). However, the 
clinical significance of oxymorphone remains debatable due to inconsistent data on 
the analgesic effects. The concentration of oxymorphone in the brain is believed to be 
too low to have a significant analgesic effect (53). However, in CYP2D6 poor 
metabolizer the analgesic effects after oxycodone were lower, which could suggest 
that oxymorphone has some clinical significance (54). Findings were based on few 









CHAPTER 2. AIMS & HYPOTHESES 
This PhD thesis is based on the results of two studies and data from an existing 
research database resulting in five scientific papers (I-V). An overview of conducted 
studies, papers and corresponding aims is illustrated in Figure 7.  
The overall aim of the PhD project was to investigate the impact of gastrointestinal 
surgery, associated with resection or bypass, on absorption of orally administered 
oxycodone formulations, and subsequently evaluate the appropriateness of such 
formulations to patients with RYGB and SBS.  
The detailed aims were:  
Aims 
I. To characterize segmental gastrointestinal pH profiles, motility measures and 
transit times in patients with RYGB, using the wireless motility capsule (WMC) 
(paper I). 
 
II. To develop and evaluate a pharmacokinetic-pharmacodynamic (PKPD) model 
of oral solution and two controlled-release oxycodone formulations in healthy 
participants (paper II). 
 
III. To develop and evaluate a PKPD model of oral solution and two controlled-
release oxycodone formulations in patients with RYGB, using the PKPD model 
established in healthy participants as a base model. Furthermore, to determine 
PKPD differences of the three oxycodone formulations between patients with 
RYGB and healthy participants (paper III). 
  
IV. To develop and verify a physiological-based pharmacokinetic (PBPK) model 
with extensive absorption characteristics for oral solution and controlled-
released oxycodone in a healthy population Furthermore, to apply the 
developed PBPK models in healthy populations of varying age, ethnicity as 
well as in patients renal and hepatic impairment (paper IV). 
 
V. To explore the pharmacokinetics of oral solution oxycodone in patients with 
short bowel syndrome (paper V).  
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Figure 7. Overview of available data and data flow in regard to the scientific papers. The data 
pool consisted of a database with WMC traces and two studies referred to as “Study 1: 
ABOXY” and “Study 2: USB”. Abbreviations: WMC: wireless motility capsule, HV: healthy 
participants, RYGB: patients with Roux-en-Y gastric bypass, SBS: patients with short bowel 
syndrome, PK: pharmacokinetic, PD: pharmacodynamic, SOL: oral solution, CRF1: lipid-based 
controlled-release formulation, CRF2: water-swellable controlled-release formulation.  
To fulfill the five aims the objectives and hypotheses were as follows:  
Objective 1 – paper I 
The first objective was to determine specific physiological differences of the 
gastrointestinal tract in patients with RYGB, which could impact and help explain 
postsurgical symptoms as well as possible absorption alterations. Hence, pH, transit 
time and motility measures were assessed, using the WMC. It was hypothesized that 
patients with RYGB would have a shorter transit and increased luminal pH of the oro-
cecal segment and no differences in the colon as compared to healthy participants.  
Objective 2 & 3 – paper II & III  
The second objective was to assess and evaluate the exposure-response relationship 
of oral solution, lipid-based and water-swellable controlled-release oxycodone in 
healthy participants and patients with RYGB, using a PKPD modelling approach. It 
was hypothesized that the PKPD relationship would deviate between the two 
mechanistically different controlled-release tablets in patients with RYGB. More 
specifically, we expected results to reflect a poor drug release from the lipid-based 
matrix, due to the altered digestive fluid composition. Furthermore, a shorter lag time 
and lower bioavailability was expected for the controlled-release tablets among 
patients with RYGB compared to healthy participants, whilst a higher absorption rate 
and bioavailability was hypothesized for the oral solution.   
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Objective 4 – paper IV  
The third objective was to develop and verify PBPK model with extensive absorption 
characteristics for oral solution and controlled-release oxycodone in a healthy 
population. This could then be used to predict pharmacokinetic outcomes in special 
populations.  
Objective 5 – paper V 
The last objective was to explore the magnitude of varying intestinal lengths on the 
absorption degree of oral solution oxycodone by performing a pharmacokinetic study 
in patients with SBS. A correlation was hypothesized to be present between intestinal 
length and the pharmacokinetic measures AUC (area under the concentration-time 




CHAPTER 3. MATERIALS & METHODS 
As mentioned, this thesis is based on data from two studies, referred to as “Study 1: 
ABOXY” and “Study 2: USB” and an existing WMC database, resulting in paper I-
V (Figure 7). As shown in Figure 7, study 1 included data from healthy participants 
and patients with RYGB. Study 2 included data from patients with SBS and from the 
WMC database supplied WMC data from healthy participants. 
Study 1 was approved by the Danish Medicine Agency (EudraCT number: 2017-
00732-34, registered at www.clinicaltrialregister.eu), the North Denmark Region 
Committee on Health Research Ethics (N-20170039) and registered at the Danish 
Data Protection Agency. Eligible participants underwent a screening session, where a 
physician evaluated their medical history to ensure that all inclusion and no exclusion 
criteria were fulfilled. Oral and written information about the study was given prior 
to signing the informed consent. If found eligible, the participant was enrolled in the 
study.  
Study 2 was a clinical investigation conducted on the basis of unsatisfactory pain relief 
reported by the patient. Thus, an approval from the medical authorities was not 
necessary according to Danish law. Nevertheless, all patients were detailed informed 
about study procedures before giving their oral consent prior to study entry.  
The WMC database has previously been approved by the North Denmark Region 
Committee on Health Research Ethics (N-2009008) and registered at the Danish Data 
Protection Agency.  
All data was collected at Department of Gastroenterology and Hepatology at Aalborg 
University Hospital and were conducted in compliance with the Declaration of 
Helsinki and International Conference on Good Clinical Practice guidelines.  
In the following sections a short description of applied materials and methods for each 
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3.1. STUDY 1: ABOXY 
Study 1 was a randomized, controlled, three-armed, semi-double blinded, cross-over 
study including 15 healthy participants and 22 patients with RYGB, whereof one 
patient with RYGB was excluded after the first treatment visit due to an adverse event 
and another withdrew her informed consent after the WMC assessment, thus before 
starting treatment visits (Figure 8).  
Specific in- and exclusion criteria were set to minimize inter-individual variability 
(e.g. ethnicity), adverse events (e.g. known allergies) and bias of obtained results (e.g. 
strong inhibitors or inducers of CYP3A4). Furthermore, several ethical considerations 
had to be taken into consideration, as oxycodone is highly addictive and has several 
severe side-effects. Hence, all participants had to be mature adults (25-80 years), 
healthy participants had to be opioid naïve1 with no present nor previous history of 
any drug abuse. Additionally, women had to assure a negative pregnancy test prior to 
each treatment visit and could not be lactating. Furthermore, RYGB surgery of 
patients had to had occurred at least one year before study inclusion, to allow time for 
gut adaption and a more stabilized weight. Finally, patients with RYGB were not 
allowed to consume oxycodone at least 1 week in advance of study inclusion and 
under the whole period of study conduct. In addition, any new needs or alterations of 
current medications were evaluated prior to treatment visits and if deemed to impact 
study results, participants were excluded from further participation.  
Figure 8 gives an overview of the study flow. As illustrated, eligible participants 
underwent a standardized assessment using the WMC assessment and 3 treatment 
visits – one for each oxycodone formulation. The order of administered oxycodone 
formulations was completely random. A computer-generated randomization list was 
generated by personnel, who were not otherwise involved in the study.  Participants 
were assigned chronologically to a randomization number as they were enrolled.   
 
 
                                                        
1 Opioid naïve is defined as a person who is not opioid tolerant (i.e. a higher dose is required to 
obtain the same amount of pain relief of previous lower doses) and who has not taken opioids 
in one week or longer. However, in this study we defined opioid naïve as a person who did not 
have a history of opioid use/addiction. If the opioids were used more than five years before the 
start of experiment as an analgesic to treat pain post-surgery etc., this person was also 
considered opioid naïve. Finally, if the person had never used opioids to treat pain but had 
participated in pain studies where opioids were given more than a year before this study, this 




Figure 8. Flow diagram for Study 1. *The order of oxycodone formulations was 
completely random from one participant to another. h: hour, WMC: wireless motility 
capsule.  
Of note, the WMC has several contraindications e.g. complications. Thus, it was not 
a requirement to undergo a WMC assessment in order to participate in study 1. This 
is also the reason why only 19 out of the included 22 patients with RYGB were 
included in paper I. One patient had gastrointestinal complications related to the 
RYGB surgery, another was allergic towards the Smartbar® content (see below) and 
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3.1.1. WIRELESS MOTILITY CAPSULE ASSESSMENT 
The WMC (SmartPill®, Medtronic, Minneapolis, USA) was used to assess segmental 
intraluminal pH, transit time and motilities indices. The technical capsule records 
body temperature (with an accuracy of 1°C), pH (with an accuracy of 0.5 units) and 
pressure (with an accuracy of 5mmHg below or 10 mmHg above 1000 mmHg) as it 
navigates through the gastrointestinal tract. Measurements are instantly transmitted to 
a portable data receiver worn by the participant. The receiver stores data until it is 
transferred to a computer and subsequently analyzed.  
Prior to study start, participants had fasted overnight and ingested a standardized meal. 
Shortly after, the SmartPill® was swallowed with 200 mL water and the data receiver 
was subsequently placed around the participant’s neck. Participants were instructed 
to wear this device until the SmartPill® was expelled from their system (receiver 
stopped recording) or for at least 5 days. Furthermore, participants were ordered to 
restrain from foods, beverages the first 6 hours post capsule ingestion and extreme 
physical activities during the entire test. Finally, participants received a dairy where 
date and time of specific daily routines (e.g. meals, bowel movements, going to bed 
and getting up and other relevant comments) could be noted during the test period.  
In this study, the analysis software MotilitiGI (version 3.0, Medtronic, Minneapolis, 
USA) was used. Two segments, oro-cecal and colonic, were distinguished from each 
other by significant alterations in temperature and pH as described by Sarosiek et al. 
(55). Contraction frequency and amplitude data was used to calculate the motility 
index, as proposed by Camilleri et al. (56). Transit time, pH and motility index was 
determined for each segment as well as for the first and last hour of each segment. 
Measurements were compared between the two populations using a linear mixed 
model. Any indication of a restriction violation was evaluated (e.g. increase in pH 
after food and liquid ingestions or temperature rise and drop after liquid ingestions) 
and data was discarded unless the temperature drop was due to limited water intake 
(e.g. rapid normalization of the temperature). Further details are reported in paper I.  
3.1.2. STUDY PROCEDURES RELATED TO TREATMENT VISITS 
Treatment visit 1-3: Participants arrived at the research unit after an overnight fast. 
Baseline measurements were obtained. These includes blood pressure, heart rate, body 
mass index (BMI), blood sample, pupil diameter and muscle pressure stimulation 
threshold and judgement of well-known side effects of oxycodone. A blood sample 
(9 mL) for evaluation of paraclinical values was collected for patients with RYGB. 
Additionally, a blood sample for genotype determination was collected (only visit 1). 
After the completion of baseline measurements, participants administered either a) 10 
mL oral solution oxycodone, b) 20 mg water-swellable matrix CRF or c) 20 mg lipid 
based CRF in a randomized order. Formulation a) was administered with 50 mL of 
water, while formulation b) and c) were administered with 240 mL of water. Blood 
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samples, pupillary measurements and muscle pressure stimulation threshold was 
subsequently conducted at specific time points over the next 24 hours. Participants 
were supplied with standardized meals during treatment visits. Naloxone was 
available in the laboratory as an antidote/rescue medication for oxycodone. Patients 
with RYGB noted any drug use in a dairy two days prior to treatment visits and we 
encouraged to take the same medication at the same time before each visit.  
Follow-up: Participants were contacted by telephone approximately 48 hours after 
each drug administration, in order to register potentially late occurring adverse 
effects/events and any opioid withdrawal symptoms. 
Wash-out: Visit 1-3 were separated by a wash-out period of at least 5 days to minimize 
the risk of a carry-over effect between treatment visits.   
3.1.2.1 Study medication 
The study medication consisted of: 
a) Oxynorm®, oral liquid mixture 1mg/ml; Norpharma A/S / Mundipharma 
A/S, Vedbaek, Denmark. 1 mL contains 1 mg oxycodone. Only 10 mL was 
administered orally.  
 
b) Oxycodone hydrochlorid “Lannacher”, controlled-release tablet 20 mg; 
Lannacher Heilmittel Ges.m.b.H, Lannach, Austria. One tablet contains 20 
mg oxycodone. Only 1 tablet was administered orally. Tablet design: 
controlled-release tablet with water-swellable matrix system. 
 
c) Oxycodone Depot “Sandoz”, controlled-release tablet 20 mg; Sandoz A/S, 
Copenhagen, Denmark. One tablet contains 20 mg oxycodone. Only 1 tablet 
was administered orally. Tablet design: controlled-release tablet with lipid-
based matrix system.  
 
The oral solution was included in the study to better elaborate upon the impact of 
RYGB on drug release from the two mechanistically different controlled-release 
tablets, as this formulation has no dissolution parameter.  
The dosage of the oral solution was half that of the controlled-release formulations, 
because its absorption is more rapid resulting with higher peak concentrations, which 
is associated with a greater risk for side-effects (57,58).  
3.1.3. ASSESSMENT OF OXYCODONE PHARMACOKINETICS 
To evaluate the pharmacokinetics of the different oxycodone formulations, venous 
blood samples were collected before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.33, 2.66, 3, 3.33, 
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3.66, 4, 5, 6, 8, 12 and 24 h after drug administration. These sampling times were 
chosen to best capture the pharmacokinetic profile of oxycodone and were based on 
previously conducted pharmacokinetic studies (11,38,59–69). Plasma concentrations 
of oxycodone, noroxycodone and oxymorphone were determined using high-
performance liquid chromatography.  
3.1.4. ASSESSMENT OF OXYCODONE PHARMACODYNAMICS 
3.1.4.1 Pupillometry 
Pupillometry, measurement of the pupil diameter, is a recognized objective method, 
to assess the pharmacodynamic effects of opioids (70–74). In the current study, 
pupillometry measurements were conducted after each blood sampling, using a digital 
infrared hand-held NeuroOptics VIP 200 pupillometer (NeuroOptics, Irvine, CA, 
USA). All measurements were performed under consistent light conditions and 
always on the same eye.  
3.1.4.2 Muscle pressure algometry 
The subjective analgesic effect of oxycodone was assessed prior to and 1, 2.5, 3, 3.5, 
4.5, 6, 12, 24 h post drug administration, using a handheld pressure algometer (Type 
2, Somedic production AB, Sweden). Stimulations were conducted on the dorsal 
forearm 10 cm distal to the elbow. Stimulations ceased once participants reached their 
pain detection threshold (first time sensation was perceived as painful), corresponding 
to a score of 5 on the modified visual analogue scale.  
Unfortunately, this data was not meaningful in regard to the analysis due to extreme 
variability. Hence, this data was discarded and is therefore not mentioned in any of 
the papers.    
3.1.4.3 Safety assessment  
To evaluate the safety of the different oxycodone formulations, the degree of 12 well-
known side-effects were rated as (0) none, (1) slight, (2) moderate, (3) high degree 
and (4) very high degree and registered prior to and 1.5, 3, 6, 12 and 24 h post drug 
administration. The 12 side-effects included nausea, dizziness, headache, stomach 
pain, itchy skin, dry mouth, vomiting, sedation, changes in heart rate, sweating, 
constipation and difficulties breathing. Any additionally mentioned side-effects were 
also registered.  
3.1.4.4 Pharmacogenomic profiling 
Pharmacogenomic tests were performed to determine each participant’s genetic make-
up in relation to specific drug metabolizing enzymes and receptors, which impacts a 
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person’s exposure and response to oxycodone. Hence, the blood samples which were 
collected during participants’ first treatment visit, were delivered to GeneTelligence 
Aps (Denmark), who analyzed the participants’ pharmacogenetic profile and 
subsequently provided a detailed Personal Medicine Profile™. The Personal 
Medicine Profile™ included information on the following genes: CYP1A2, CYP2B6, 
CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DPYD, IFNL3, OPRM1, 
SLCO1B1, TPMT, UGT1A1, and VKORC1. Genotypes were translated to 
phenotypes by the GeneYouIn PillCheck™ “black-box” technology, which uses data 
from PharmGKB, PharmVar, CPIC, FDA and EMA. The genotyping was performed 
by the State Serum Institute, Copenhagen, Denmark, using Agena’s MassARRAY® 
system and validated using AgenaBio® ADME assays.  
Unfortunately, these results were obtained late during the project period and thus only 
used in paper IV.  
3.1.5. POPULATION PHARMACOKINETIC-PHARMACODYNAMIC 
MODELLING 
The PKPD relationship of oral solution, lipid-based and water-swellable controlled-
release oxycodone was determined for healthy participants and patients with RYGB 
by fitting population data, obtained in study 1, to models using the nonlinear mixed 
effects modelling tool NONMEM® (version 7.4; ICON Development Solutions, 
Ellicott City, MD) with the Wings for NONMEM interface 
(http://wfn.sourceforge.net) and IFort compiler. In addition, the first order conditional 
estimation with interaction (FOCE-I) method was used. 
A PKPD model was first developed in healthy participants (paper II). This model was 
then used as a base/reference model to further develop a PKPD model in patients with 
RYGB (paper III). This model could then distinguish PKPD differences among 
patients with RYGB as well as between healthy- and patient participants.  
A general modelling procedure applied for both model developments. As described 
by Ladebo et al. (2020) in paper II, models were developed using a sequential PKPD 
modelling approach:  
“… whereby the PK component of the model was developed first, with the PD model 
developed sequentially using the PPP&D (Population PK Parameters and Data) 
method with the PK model parameters fixed at the previously determined values and 
the PK data retained during the PD model estimation step (75). Processing NONMEM 
output and generating plots were conducted with the R software (76) (Version 3.3.3 
or later) using gglot2, plyr, doBy and scales packages and their associated 
dependencies.  
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Selection criteria for the base model were based on mechanistic plausibility, a 
statistically significant (P < 0.05) improvement of the fit (3.8-unit decrease in the 
objective function for the addition of a single parameter) and visual inspection of 
standard goodness-of-fit diagnostic plots. The final model was also required to pass 
the covariance step. Visual predictive checks (VPC) based on 1000 simulations of the 
index dataset were used to evaluate the predictive performance of the adequacy of the 
final model in describing the observed data. 
Potential significant covariates were identified by visualizing plots of covariates 
versus between-subject variability (BSV) of parameter estimates. Physiologically 
plausible covariates (eg. vomit, sex, age) were evaluated for statistical significance 
using a stepwise covariate modelling of forward addition and backward elimination 
(77). The statistical criteria for retaining a covariate in the model were P < .01 during 
forward addition and P < .001 for backward elimination.“ (78)  
For the specific details on the two modelling strategies, please see paper II and III.  
3.1.6. PHYSIOLOGICAL-BASED PHARMACOKINETIC MODELLING 
The Simcyp Population-based ADME Simulator (version 18.2, Certara UK Ltd., 
Simcyp Division, Sheffield, UK) was used to develop two oxycodone PBPK models 
(Model I: oral solution (also termed immediate-release in paper IV) and Model II: 
controlled-release) in healthy Caucasians.  
Detailed information on the modelling approach can be found in paper IV.  
In brief, Model I was built first using physiochemical data combined with in vitro 
information on metabolism and permeability. Absorption was described using the 
“Advanced Dissolution Absorption and Metabolism” (ADAM) model, which is 
embedded within the Simcyp Simulator. The model was refined by sensitivity analysis 
of specific parameters and verified against 16 clinical pharmacokinetic studies (8 per 
oral single dose, 1 per oral multiple dose, 7 drug-drug interaction studies). The model 
was accepted if the simulated pharmacokinetic parameters (AUC, Cmax, Tmax) were 
within 0.7-1.3-fold error of the corresponding observed values (79). Model II was 
developed using Model I as baseline. The formulation type was then altered to 
monolithic controlled-release and dissolution data added. This model was verified 
against 2 per oral single dose pharmacokinetic studies. Finally, the two verified 
models were further extended to specific populations: i) healthy >65 years, ii) healthy 
Japanese, iii) healthy Chinese iv) patients with moderate and severe renal impairment, 
and v) patients with cirrhosis Child-Pugh class A-C. These populations were all found 
within the Simcyp default library and have previously been verified. The simulated 




3.2. STUDY 2: USB  
Study 2 was an explorative case series including 6 patients with short bowel syndrome 
(type III). Each patient was allocated into one of three categories:  1) jejunostomy < 
50 cm small intestine, 2) jejunostomy with 50-150 cm preserved small intestine, and 
3) jejunocolic anastomosis. All participants underwent a pharmacokinetic assessment 
of 10 mg oral solution oxycodone. Blood samples were collected at specified time 
point before and up to 6 hours after drug administration. Oxycodone plasma 
concentrations were determined by high-performance liquid chromatography and 
noncompartmental analysis was used to obtain pharmacokinetic parameters. Specific 
baseline characteristics was collected from the patients’ medical records and used to 
evaluate the pharmacokinetic outcomes both among patients and between patients and 
reference values. For specific study details please refer to paper V.  

CHAPTER 4. KEY RESULTS 
The following section summaries the key results in regard to the proposed aims in 
chapter 2. Detailed results are reported in the papers.  
Paper I: “Gastrointestinal pH, motility patterns and transit times after Roux-en-
Y gastric bypass” 
Aim I 
To characterize segmental gastrointestinal pH profiles, motility measures and transit 
times in patients with RYGB, using the wireless motility capsule.  
Key results 
• In comparison to healthy, the oro-cecal segment of patients with RYGB was 
characterized by a more alkaline microenvironment (P < 0.001), high 
motility activity (P < 0.012) and short transit (P < 0.001).  
• In addition, transit of the colon was prolonged in patients with RYGB (P = 
0.048).   
Interpretation 
These findings reflect the anatomical changes following RYGB surgery. The findings 
were not overly surprising; however, it is important to systematically determine 
differences to help explain possible absorption alterations as well as post-operative 
complications, which these patients may experience.   
Paper II: “Population pharmacokinetic-pharmacodynamic modelling of 
immediate and controlled-release formulations of oxycodone in healthy 
volunteers” 
Aim II 
To develop and evaluate a PKPD model of oral solution and two controlled-release 
oxycodone formulations in healthy participants. 
Key results 
• The pharmacokinetics of oxycodone was best described by a two-
compartment model with first order absorption. 
• No differences in the PKPD relationship were found between the two 
controlled-release formulations.  
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• The absorption rate was approx. 80 % lower for controlled-release tablets as 
compared to the oral solution.  
• Tablets had an absorption lag of 23 minutes. 
• The pharmacodynamics was best described by a proportional Emax model.   
• Males had approximately a 40 % lower plasma concentration at EC50 (half 
maximal effective concentration).   
Interpretation  
Generic substitution of the two controlled-release formulations is safe in persons with 
a healthy, intact gastrointestinal tract. The pharmacokinetic profile of the oral solution 
vs. controlled-release tablets was consistent with known release profiles. In addition, 
the pharmacodynamic model indicated oxycodone to be more potent in males. This 
PKPD model may serve as reference/base for future patient PKPD models. 
Paper III: “Effect of Roux-en-Y gastric bypass on the pharmacokinetic-
pharmacodynamic relationships of liquid and controlled-release formulations of 
oxycodone” 
Aim III  
To develop and evaluate a PKPD model of oral solution and two controlled-release 
oxycodone formulations in patients with RYGB, using the PKPD model established in 
healthy participants as a base model. Furthermore, to determine PKPD differences 
of the three oxycodone formulations between patients with RYGB and healthy 
participants. 
Key results 
• A PKPD model was successfully developed using the PKPD model 
established in healthy participants.  
• No PKPD differences were found between the two controlled-release 
formulations in patients with RYGB.  
• Patients with RYGB had an absorption lag, which was 2.5 minutes shorter 
than healthy participants (P < 0.001). 
• Bioavailability was 14.4 % higher in patients compared to healthy controls, 
regardless of formulation type (P < 0.001). 
Interpretation  
This PKPD model can be used to determine pharmacokinetic and pharmacodynamic 
differences on two levels: 1) between the two controlled-release tablets in patients 
with a RYGB and 2) between patients with RYGB and healthy controls. In addition, 
monophasic lipid-based and water-swellable controlled-release oxycodone tablets 
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may be generically substituted in patients with RYGB. Finally, the shorter lag time 
observed for patients with RYGB is not expected to be of clinical significance. 
However, dose adjustments may be required to prevent serious side-effects, due to the 
increased oral bioavailability of oxycodone.  
Paper IV: “A physiological based pharmacokinetic model of immediate and 
controlled-release oxycodone: Absorption refinement and extended application”  
Aim IV  
To develop and verify a PBPK model with extensive absorption characteristics for 
oral solution and controlled-released oxycodone in a healthy population 
Furthermore, to apply the developed PBPK models in healthy populations of varying 
age, ethnicity as well as in patients renal and hepatic impairment.   
Key results 
• A full PBPK was successfully built and verified for oral solution and 
controlled-release oxycodone in healthy adults.  
• Absorption was described with the ADAM model.  
• 90 % of the simulated versus observed pharmacokinetic parameters (AUC, 
Cmax, Tmax) were within 0.7-1.3-fold difference.  
• Simulations using the final models indicated that healthy persons > 65 years 
had 1.5-fold higher AUC, when compared to simulated results in healthy 
Caucasians.  
• Simulations in healthy Japanese and Chinese adults revealed a 1.3- and 1.5-
fold increase in AUC, respectively, as compared to simulated data in healthy 
Caucasians. 
• Simulations in patients with moderate and severe renal impairment revealed 
a 1.6-fold increase in AUC, as compared to simulated data in healthy 
Caucasians.  
• Simulated AUC was 1.5-, 2.5- and 3.2-fold higher in patients with cirrhosis 
Child-Pugh class A, B and C, respectively, as compared to simulated results 
in healthy Caucasians. 
• Overall, simulation outcomes in the respective populations were in 
reasonable agreement with observed data.  
Interpretation  
These models may be used to predict the pharmacokinetics of oxycodone of different 
drug-drug interaction scenarios, dosing regimens and in populations of varying age, 
ethnicity and in patients with renal and hepatic impairment. The simulations indicate 
that dose adjustments of oxycodone are required in patients with renal and hepatic 
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impairment. In addition, healthy elderly as well as Japanese and Chinese persons may 
also need dose adjustments. 
Paper V: “Oral absorption of opioids in patients with short bowel syndrome” 
Aim V 
To explore the pharmacokinetics of oral solution oxycodone in patients with short 
bowel syndrome.  
Key results 
• All six patients with short bowel syndrome absorbed clinically relevant 
concentrations of oxycodone. 
• The total intestinal length tended to correlate positively with the relative 
bioavailability of oxycodone.  
• Preservation of the colon had a positive effect on the relative bioavailability 
of oxycodone. 
Interpretation  
Patients with short bowel syndrome may be treated with oral solution oxycodone, 
although drug dosing must be individualized according to the patient’s functional 






CHAPTER 5. DISCUSSION 
Work conducted as part of this thesis investigated aspects of how gastrointestinal 
surgery, associated with bypass or resection, impacts the absorption of orally 
administrated oxycodone. In summary the following was characterized:  
• specific physiological alterations of the gastrointestinal tract following 
RYGB (paper I)  
• the PKPD-relationship of oral solution, lipid-based and water-swellable 
controlled-release oxycodone in 15 healthy participants and 21 patients with 
RYGB (paper II & III)  
• a full PBPK model of oxycodone after administration of an oral solution and 
a controlled-release formulation (paper IV)  
• the pharmacokinetic profile of oral solution oxycodone in 6 patients with 
short bowel syndrome (paper V) 
This section will first address the strengths and limitations of the clinical studies 
(Study 1: ABOXY and Study 2: USB). This is then followed by methodological 
considerations of the applied techniques. Lastly, the clinical findings and potential 
implications will be discussed.  
5.1. STRENGTHS AND LIMITATIONS OF THE CLINICAL 
STUDIES 
A perfect clinical trial is impossible to construct, as compromises must be made either 
due to ethical or practical reasons.  
5.1.1. STUDY PARTICIPANTS 
Selecting in- and exclusion criteria is a balance between obtaining clear scientific 
answers, producing generalizable results and reflecting clinical reality.  
 
A major limitation of the clinical studies conducted was the co-administration of 
different medications among patients, which could potentially bias pH and transit 
measures (paper I) as well as pharmacokinetic and pharmacodynamic parameters 
(papers III and V). Nonetheless, we wished to reflect the clinical setting and ensure a 
rapid recruitment, which would otherwise be difficult and perhaps also unethical and 
irresponsible, if participants had to refrain from their daily medications. In addition, 
the effects of CNS agents were tested both in paper I and paper III and results indicated 
that these agents did not affect neither transit time (paper I) nor the PKPD-relationship 
of oxycodone in patients with RYGB (paper III). Furthermore, patients were 
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instructed to administer their medications consistently 2 days prior to study visits, 
which could help minimize intra-individual variation. 
An inclusion criterion for patients with RYGB was that their surgery had to be 
conducted a year in advance of study start, however, there was no maximum limit for 
how long ago it had taken place. Thus, the number of years since the operation was 
performed varied widely among participants with RYGB. This could potentially 
introduce additional inter-individual variability as the effects of enteroplasticity 
changes over time. Possible effects of enteroplasticity include: 1) morphological 
alterations of the villi length, crypt depth and/or total number (80), 2) enteroendocrine 
changes of gastrointestinal peptides such as glucagon-like peptide-1 (81), 3) nervous 
system adaptions affecting innervation and neuron activity, and 4) nutrient signaling 
adaptions where the number of nutrient transporters increase (82). These factors may 
play an important role in drug absorption. Furthermore, enteroplasticity also occurs in 
patients with SBS (23,24), thus this may also have influenced results in paper V to an 
unknown degree.  
Psychological conditions such as depression and anxiety are common both before and 
after bariatric surgery (83). Thus, the comprehensiveness of, especially, study 1 may 
have discouraged some patients from participation. Hence, study participants may 
compose a selected group. In addition to the long list of in-and exclusion criteria (e.g. 
North European descent), this may minimize the generalizability of results.  
5.1.2. STUDY DESIGN 
Study 1 was a randomized, cross-over study with three treatment arms. This type of 
study is at the top of the hierarchy of clinical evidence. Nevertheless, inclusion of a 
placebo arm would have been beneficial in order to control for the effects of co-
medications on both pharmacokinetic and pharmacodynamic measures. Furthermore, 
it would allow to control for circadian alterations of the pupil diameter (84). However, 
this was not a part of the study design, because it would increase the 
comprehensiveness of the study and potentially make patient recruitment more 
difficult. In addition, we were primarily interested in determining any differences in 
drug release and thus absorption between the two controlled-release formulations. The 
inclusion of the oral solution, as a third treatment arm, was important in regard to this. 
As previously mentioned, participants were also advised to administer their daily 
medications consistently two days prior to treatment visits. Thus, we assumed a 
uniform effect of co-medications on oxycodone pharmacokinetics and 
pharmacodynamics.  
As study 1, was the first study investigating how altered GI-physiology affects release 
of oxycodone from controlled release formulations, no proper sample size calculation 
could be provided. Thus, the sample size was based on previous bioequivalence 
studies, which usually include 12-24 study participants (85) as well as previous 
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pharmacokinetic studies conducted in patients with RYGB, where the participant 
number ranged between 5-34 (4,5). We considered 15 healthy participants and 20 
patients with RYGB to be sufficient to determine PKPD differences between the 
different formulations, which was the primary aim.  
Study 2 was a case series with information on six patients with SBS. This study design 
was chosen due to its’ simplicity. Patients with SBS are very heterogenous and rather 
vulnerable patients. Recruitment for larger and more comprehensive studies such as 
randomized controlled trials can therefore be very difficult. A case series is a weak 
type of study due to possible selection bias and limited power. Assessment of potential 
confounders was therefore not possible in paper V. Nevertheless, case series can 
provide useful information for theoretical hypothesis and thus limit unethical 
conductance of larger trials.  
5.2. METHODOLOGICAL CONSIDERATIONS 
5.2.1. WIRELESS MOTILITY CAPSULE  
To date, the wireless motility capsule is the only method that can simultaneously 
determine regional gastrointestinal transit, contractility and pH patterns. In addition, 
it has several other advantages such as being minimally invasive, time efficient and 
does not require inpatient care. The method is also highly standardized and data is 
easy to interpret. Nevertheless, its use in patients with RYGB was challenged (paper 
I). For instance, it was not possible to distinguish the pouch from the small intestine, 
as pH changes were not significant. Other techniques such as scintigraphy may 
therefore be more useful to determine the exact transit between these two regions, 
although scintigraphy exposes participants to radiation and is rather expensive and 
time-consuming (86). This technique has previously been applied in patients with 
RYGB and found accelerated gastric emptying (87–90).  
The Smartbar® is an element of the wireless motility capsule system and was used as 
a standardized meal in paper I. Nonetheless, approx. 60 % of participants with RYGB 
were unable to ingest the entire Smartbar®, due to nausea and fear of dumping 
syndrome, which could result from the carbohydrate-rich content (91). This may have 
biased results, as meal content and volume has shown to impact transit time (88,90). 
Although, the post-hoc analysis performed in paper I did not find such associations. 
We still recommend future studies to consider a tailored standardized meal depending 
on the population of interest. Apart from patients with RYGB, this could also be of 
relevance for diabetics, who may experience hyperglycemia, which can decelerate 
gastric emptying (92). Based on the current nutritional recommendations (93), a small, 
solid but easily chewable, protein-rich meal may have been a more suitable meal for 
patients included in paper I.   
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Lifestyle differences (e.g. eating habits, physical activity) between healthy 
participants and patients with RYGB may also have biased, especially, transit 
measures to an unknown degree (94). Such confounders could be eliminated if 
participants were monitored until capsule expulsion. Though, this would make the 
study extremely comprehensive. Instead, participants were advised to refrain from any 
foods or liquids (except limited quantities of water) the first 6 hours of the test period. 
In addition, extreme physical activity was not allowed during the entire test. None of 
the traces indicated violation of substance ingestion, however performance of physical 
activity could not be evaluated. Thus, we could only trust that participants would obey 
the study restrictions.   
5.2.2. PHARMACOMETRIC METHODS  
Modelling techniques are cost-effective analytical tools, which apply mathematical 
equations to describe and better understand the interaction between drugs and humans. 
Such information is useful for drug development, regulatory assessments, 
optimization of dosing regimens, and designing better clinical trials. The reliability of 
models is, however, dependent on the quality of existing input data as well as the 
modelling strategies applied. Simulation outputs must therefore be interpreted and 
used carefully, as they will not be entirely realistic.  
In this PhD project, two pharmacometric methods were applied, namely PKPD and 
PBPK modelling.  
PKPD models describe the exposure-response relationship as a function of time by 
fitting models to population data. Hence, PKPD modelling greatly replies on empiric 
data, which also means that a population mean as well as interindividual and residual 
variability of both pharmacokinetic and pharmacodynamic changes can be 
characterized (95,96). This is useful for establishing safety margins and optimal 
dosing regimens for a specific population (97). In contrast, PBPK models describe the 
pharmacokinetics of drugs by physiological parameterized compartments, 
representing organs and tissue function, as well as known flow rates of the circulating 
system, which connects the compartments (98). Models also incorporate data on the 
physiochemical properties of the drug of interest as well as trial design information. 
Thus, PBPK models can simulate clinical scenarios (e.g. different dosage regimens 
and drug-drug interactions) in different populations including healthy persons of 
varying ages, ethnicity as well as post-surgery or in diseased patients (e.g. patients 
with gastric bypass or short bowel) etc. This is beneficial in regard to answering very 
specific questions related to physiological changes as well as guiding dosing regimens 
for, especially, sensitive populations such as pediatrics, pregnant women and patients 
subjected to bariatric surgery. Like PBPK models, PKPD models also apply 
compartments to describe drug pharmacokinetics, however, these are much more 
simplified and not always physiologically meaningful. PKPD models may incorporate 
intrinsic (e.g. age, weight) and extrinsic factors (e.g. food, co-medication) that are 
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considered biological plausible, however the physiological impact will never be as 
detailed as in PBPK models. Finally, PBPK models are easy to conceptualize, as user 
friendly software is available (e.g. SimcypTM, GastroPlus® and PK-Sim®). However, 
users must be aware of the many assumptions and limitations behind the in vitro-in 
vivo extrapolations and various sub-models to fully understand and accurately apply 
model predictions.  
In summary, the two modelling approaches can answer different pharmacology 
questions, thus complementing each other well. Hence, the emerging field of 
“personalized medicine” may benefit from combining PBPK models with fully 
mechanistic pharmacodynamic models that also incorporate individual variability, 
which PBPK currently lack.  
In the following two sections specific modelling considerations of paper II-IV will be 
discussed.  
5.2.2.1 PKPD modelling  
In paper III, the developed PKPD model from paper II was used as a baseline model 
to determine the PKPD-relationship of the same formulations in patients with RYGB. 
This approach may be overruled by analyzing all data in one analysis, which 
potentially could increase the power of the PKPD study and allow a more systematic 
evaluation of the influence of formulation, patient group, age etc. Hence, this could 
be interesting to verify and thus update the current results of paper III.  
In paper II and III, oxycodone plasma concentrations and pupil diameter 
measurements were successfully used to assess the PKPD-relationship of oral 
solution, lipid-based and water-swellable controlled-release oxycodone in healthy 
participants and patients with RYGB. Nevertheless, the model could have benefitted 
from additional pharmacokinetic and pharmacodynamic measures such as metabolite 
plasma concentrations and muscle pressure stimulation threshold measurements, 
respectively. Initially, these data were collected, however, it was not possible to 
determine metabolite concentrations adequately and results of the muscle pressure 
stimulations were not meaningful due to high variability. In addition, the degree of 
side-effect scores seemed to follow the dynamics of oxycodone concentrations (paper 
III), thus it could have been interesting to include these side-effect metrics in the 
model. Ideally, this would require that the safety assessment be validated as a 
pharmacodynamic measure. Furthermore, it could have been interesting to investigate 
the effects of different CYP2D6, CYP3A4 and µ-, δ-and κ-opioid receptor (OPRM1, 
OPRD1, OPRK1) polymorphisms, as these may have a significant impact on both 
oxycodone exposure and response (54,99,100). Unfortunately, these data were 
obtained late in the modelling process and thus not a part of the PKPD models in paper 
II and III.  
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5.2.2.2 PBPK modelling  
One of the main limitations of the oxycodone PBPK model (Paper IV) is the 
inconsistent data on physiochemical properties. In addition, some parameters have 
only been determined in animals (e.g. B/P). This limits the validity of our model and 
may be improved by determining these values in humans.  
Like the PKPD model, metabolites were not incorporated within the model, however 
this could improve the model, especially, for future drug-drug interaction simulations.  
The PBPK models were applied in different populations and simulations were 
qualitatively compared to observed data of similar populations. In some cases, a 
quantitative comparison could have been conducted (e.g. healthy Japanese and 
Chinese) and would have been superior to the qualitative statements of paper IV.  
Finally, the absorption was described using the ADAM models, which allows for 
further exploration of oxycodone pharmacokinetics in patients with different 
gastrointestinal dysfunctions, once these populations have been validated.  
5.3. IMPACT OF GASTROINTESTINAL SURGERY ON DRUG 
ABSORPTION 
5.3.1. PHYSIOLOGICAL ALTERATIONS 
The accelerated oro-cecal transit (paper I), shorter absorption lag time for controlled-
release tablets (paper III) and overall increased oxycodone bioavailability in patients 
with RYGB (paper III) could suggest that drugs are more rapidly available for 
absorption in the jejunum as compared to healthy participants. This seems plausible 
due to the anatomical changes and is in line with other pharmacokinetic studies 
finding shorter Tmax and higher Cmax and AUC (4).  
Paper I revealed that patients with RYGB have a more alkaline intraluminal 
environment. Drug dissolution, solubility, lipophilicity and permeability is influenced 
by the degree of ionization, which depends on pH. Thus, depending on the acid 
dissociation constant, drug absorption may be more or less affected. The higher gastric 
pH may be of great importance for the bioavailability of oxycodone, which was 
increased in patients with RYGB (paper III). Results from an animal model 
demonstrated that bioavailability of sublingual oxycodone spray was 70 % at pH 9 
and only 45 % at pH 4 (101). As oxycodone is a weak base (pKa = 8.53), higher pH 
will increase the amount of unionized oxycodone, which limits water solubility and 
the fraction available for permeation. On the other hand, unionized oxycodone is more 
lipophile, which increases the permeation rate. Hence, this indicates that the 
lipophilicity of oxycodone is more important than its water solubility. Weather this 
also applies in the intestine, where the surface area for absorption is much larger than 
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the oral cavity is questionable. The use of physiologically-based pharmacokinetic 
modelling may help answer this question as well as determine the impact of altered 
drug absorption and gut wall metabolism caused by physiological alterations of the 
surgery.  
In paper V, preservation of the colon seemed to increase oxycodone bioavailability 
greatly. This could be due to colonic adaption (24) or increased GLP-1 or GLP-2 
secretion from colonic L cells (22), which all favor the process of absorption by 
increasing the absorptive capacity, slowing motility and enhancing blood flow, 
respectively (23).  
5.3.2. FORMULATION CHOICE – DOES ONE SIZE FIT ALL?  
The physiological alterations following gastrointestinal surgery, whether associated 
with resection or bypass, challenges the use of oral formulations.  
Paper III revealed no pharmacokinetic nor pharmacodynamic differences between the 
two controlled-release formulations and generic substitution was therefore considered 
safe in patients with RYGB. This was not in agreement with our hypothesis, and 
suggested drug release between the two controlled-release formulations to be equal 
and unaffected by the physiological alterations following RYGB surgery. 
Concurrently, the result was relieving, as an effectuation of new guidelines on 
formulation choice was not necessary. Nonetheless, the bioavailability of the three 
tested oxycodone formulations was approximately 14% higher in patients with RYGB 
compared to healthy participants. Initial dosages may therefore need to be reduced 
regardless of formulation. Though, the clinical significance still needs to be addressed.  
Furthermore, the uniform increase in bioavailability among the different formulations 
could suggests that the that physiochemical drug properties are superior to the 
formulation design, when it comes to altered pharmacokinetics in patients with 
RYGB. This would also explain why only some drugs show altered pharmacokinetics, 
irrespective of the formulation type, in patients with RYGB (4,102). Contradictory, 
Yska et al. demonstrated opposing bioavailability between immediate-release and 
controlled-release metoprolol before and after RYGB (9). However, the study was not 
a cross-over study and included few patients with large intra- and interindividual 
variability, thus questioning the reliability of the results.  
 
The small intestine is the most vital organ for intestinal absorption, thus it was 
expected and in agreement with previous findings (28), that patients with SBS showed 
impaired oxycodone absorption (paper V). More importantly, results of paper V 
indicated a trend between total intestinal length and relative oxycodone 
bioavailability. Similar trends using oral antibiotics in children have been 
demonstrated (103), although contradictory findings also exist (104,105). 
Nevertheless, it could be of outmost relevance to verify this trend by conducting a 
larger clinical study, that assessed the pharmacokinetics of several medications in 
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relation to functional intestinal length. A study with more power, would allow to 
control for potential confounders and covariates, thus giving a more confident result 
as compared to case studies. Another interesting trend observed in paper V was the 
positive correlation between total parenteral nutrition and fraction absorbed. This 
could simultaneously be investigated and has also been suggested previously 
(106,107).  
Overall, patients with RYGB and SBS were able to orally absorb clinically significant 
amounts of oxycodone, although with some pharmacokinetic variation compared to 
healthy participants. Based on the current data:  
1) Both oral liquid and solid dosages forms may be used in patients with RYGB, 
however, bioavailability may be altered significantly, thus requiring dose 
adjustments from general dosing guidelines and close monitoring of 
especially narrow therapeutic drugs.  
 
2) Oral liquid dosages forms may be used in patients with SBS, however, dosing 
regimens must be individualized in accordance to the patient’s characteristics 
such as functional intestinal length, renal and hepatic function. Drug 
prescribing may therefore become a rather extensive task. Thus, parenteral, 
sublingual, transdermal, rectal or buccal administration forms may be more 
appropriate and can ensure a better therapeutic effect.    
In summary, one formulation does not fit all and should ideally be selected carefully, 
depending on the patient’s characteristics and the physiochemical drug properties. 
This may not only apply to the investigated populations included in this thesis, but 
also to other populations, where the gastrointestinal physiology is altered. This could 
be in patients with inflammatory bowel diseases or irritable bowel syndrome, who 
have altered gastrointestinal transit, fluid composition, permeability and enzyme 
expression (108). It could also be of relevance to patients with chronic pancreatitis, 
who suffer from fat malabsorption, due to loss of exocrine pancreatic enzyme 
production (109), which may impact drug absorption from lipid-based formulations. 
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CHAPTER 6. CONCLUSION 
This PhD thesis had four objectives divided into five aims. In conclusion, it has 
demonstrated that:  
Aim I (paper I) 
• The anatomical alteration following RYGB surgery was suitably reflected by 
an increased intraluminal pH, shorter transit and increased motility of the 
oro-cecal segment.  
• Transit of the colon was longer in patients with RYGB. This may be 
explained by gut adaption or confounding factors such as opioid 
consumption.  
• Alterations may impact drug release and absorption of pH-sensitive 
formulations and/or drugs. In addition, results may be useful for 
understanding the underlying pathophysiology following RYGB surgery.  
Aim II-III (paper II and III) 
• A PKPD model of oral solution, lipid-based and water-swellable controlled-
release oxycodone was successfully developed in healthy participants and 
patients with RYGB.  
• The model did not find any pharmacokinetic nor pharmacodynamic 
differences between the two controlled-release formulations for any of the 
populations, thus generic substitution of these formulations may be 
considered safe in both populations.  
• A higher bioavailability of oxycodone was demonstrated in patients with 
RYGB, which may imply slightly lower initial doses and monitoring of side-
effects.    
• Further PKPD and PBPK modelling may help explain the increased 
bioavailability in patients with RYGB and further guide dose adjustment.  
Aim IV (paper IV) 
• A full PBPK model for oral solution and controlled-released oxycodone was 
successfully developed and verified. In addition, the PBPK models were 
applied in special populations and simulations were in reasonable agreement 
with observed data.  
• The PBPK model may be used to predict different clinical scenarios (e.g. 
drug-drug interactions, multiple dosing etc.).  
• The model may also be used to investigate the impact of bariatric surgery as 
well as other gastrointestinal diseases on the pharmacokinetics of oxycodone 
from different formulations, as the ADAM model was applied.  
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Aim V (paper V) 
• Absorption of oxycodone was clearly marked by the reduced functional 
intestinal length of patients with SBS.  
• Preservation of the colon seemed essential for absorption enhancement.  
• Individualized drug therapy is needed due to large variability among patients 
with SBS.  
• Functional intestinal length as well as total parenteral nutrition may be useful 
measures to adjust dosing regimens for patients with SBS.  
Overall, our results showed that gastrointestinal surgery, associated with resection or 
bypass, impacts the absorption of orally administered oxycodone.  
 In patients with RYGB, the physiochemical properties of a drug may be superior 
to the formulation design in regard to altered drug pharmacokinetics. Hence, any of 
the tested formulations may be prescribed to patients with RYGB, however, the 
increased bioavailability of oxycodone may necessitate dose adjustments to prevent 
side-effects such as addiction and tolerance. This may be addressed using a 
combination of PKPD and PBPK modelling.  
 In patients with SBS, lack of functional intestine tended to deteriorate the 
absorption of oxycodone. Nevertheless, oral solution oxycodone may be used in 
patients with SBS, although drug dosing must be individualized and will for most 
presumably require higher doses to obtain therapeutic efficacy. 
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CHAPTER 7. FUTURE PERSPECTIVES 
As a result of the work conducted, during this PhD project, new research ideas arose 
and could be of relevance to address in the future.  
 Firstly, it could be informative to address the physiological reason behind the 
increased bioavailability observed in patients with RYGB. Thus, we intend to build 
and verify a RYGB population within the Simcyp Simulator and thus apply the 
developed oxycodone PBPK models to evaluate this. Concurrently, different clinical 
scenarios could be investigated.  
 Secondly, the developed PBPK models in paper IV may be used to further 
investigate oxycodone pharmacokinetics in populations with different gastrointestinal 
diseases, specific drug-drug interaction scenarios, effects of multiple dosing as well 
as other relevant clinical situations. Such information may help optimize current 
treatment guidelines for the investigated populations.  
 Thirdly, despite no PKPD differences of the two tested controlled-release 
formulations in patients with RYGB. This may not apply to other modified-release 
formulations as well as other populations with gastrointestinal dysfunction. Prior 
investigations applying suitable dissolution systems, such as the gastrointestinal 
simulation system (GISS) developed by Yska et al. (110), or development of PBPK 
models is recommended, as such evidence may be able to answer speculations with 
reasonable probability before conducting time-consuming and costly clinical trials.  
 Finally, it could be interesting to asses functional intestinal length as well as total 
parenteral nutrition as predictive measures for both Cmax and fraction absorbed in 
patients with SBS. Such information could be used to develop a model, that could 
guide physicians to ensure safer and more optimal drug usage rather than the current 
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